Technical Feasibility of Implementing and Commercializing a Machine Learning Model for Rare Disease Prediction

Technical Feasibility of Implementing and Commercializing a Machine Learning Model for Rare Disease Prediction

Wild-type transthyretin amyloid cardiomyopathy is an under-recognized cause of heart failure. Pfizer previously developed a machine learning model that performed well in identifying wild-type transthyretin amyloid cardiomyopathy vs. nonamyloid heart failure. However, challenges exist when introducin...

Full description

Bibliographic Details
Main Authors: George Koutitas, Kimberly Nolen, Sepideh Attal, Anastasios Ventouris, Yinnon Dolev, Hans Thijs Van Den Broek
Format: Article
Language:English
Published: IEEE 2023-01-01
Series:IEEE Access
Subjects:
Artificial intelligence
commercialization
data privacy
machine learning
transthyretin amyloid cardiomyopathy
Online Access:https://ieeexplore.ieee.org/document/10196444/

Internet

https://ieeexplore.ieee.org/document/10196444/

Similar Items